Sands Capital Life Sciences Pulse Fund II. L.P. 13D and 13G filings for DICE Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-06-22 4:32 pm Sale |
2023-06-20 | 13D | DICE Therapeutics, Inc. DICE |
Sands Capital Life Sciences Pulse Fund II. L.P. | 1,886,470 4.000% |
-1,262,500 (-40.09%) |
Filing |
| 2021-09-24 6:12 pm Purchase |
2021-09-17 | 13D | DICE Therapeutics, Inc. DICE |
Sands Capital Life Sciences Pulse Fund II. L.P. | 3,148,970 8.700% |
3,148,970 (New Position) |
Filing |